Prothena | PRTA - Current Assets


Prothena reported $315.19M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Akebia Therapeutics USD 252.96M 5.38M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Exelixis USD 1.44B 41.03M Dec/2025
Immunic USD 39.27M 20.57M Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Prothena USD 315.19M 24.78M Dec/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xoma USD 110.71M 5.78M Sep/2025